Nogapendekin alfa inbakicept
As of the edition of 20 October 2026, Nogapendekin alfa inbakicept is a protein: marketed, first approved in 2024 (US); acts on IL15RA, IL2RB and IL2RG; US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Protein
- Brand name
- Anktiva
- First approved
- 22 April 2024 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Immunitybio; 2 holders in all
- Registered trials
- 20, 6 stopped early
- Disease areas
- Cancer; Immune system; Infections; Lungs and airways; Blood and lymph; Urinary and reproductive
US protection
US protection ends in 2036.
US protection ends in 2036, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Altor BioScience. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 7 | 1 | 4 | 2 |
| Phase 2 | 9 | 1 | 7 | 1 |
| Phase 3 | 3 | 0 | 0 | 3 |
| All trials | 20 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Altor BioScience | Originator | 2024 to now |
| Immunitybio | Applicant and Lead sponsor of trials | 2025 to now |